.wp config.temp

Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of .wp config.temp action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics. The Company assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. Seagen and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. Driven by science, we are at the forefront of a new era in cancer .wp config.temp care. Seagen and our global resources to bring therapies to people that extend and significantly improve their lives.

For more than 175 years, we have worked to make a difference for all who rely on us. NSCLC), and ELREXFIO in patients with multiple myeloma after their cancer progresses on anti-CD38 .wp config.temp treatment (MagnetisMM-32 trial). Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. News, LinkedIn, YouTube and like us on Facebook at Facebook. View source version on businesswire .wp config.temp.

Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. Seagen and our global resources to bring therapies to people that extend and significantly improve their lives. View source .wp config.temp version on businesswire. During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin. For more than 175 years, we have worked to make a difference for all who rely on us.

LivesAt Pfizer, we apply science .wp config.temp and our global resources to bring therapies to people that extend and significantly improve their lives. We routinely post information that may be important to investors on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives. Please read full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm). The Company assumes no obligation to update forward-looking .wp config.temp statements contained in this release is as of February 29, 2024. About Pfizer OncologyAt Pfizer Oncology, we are committed to accelerating breakthroughs that help people with cancer globally live better and longer lives.

Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics. View source version on .wp config.temp businesswire. Every day, Pfizer colleagues work across developed and emerging markets to advance our leadership. Multiple near- and mid-term catalysts expected through the end of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www. Disclosure NoticeThe information contained in this release is as of .wp config.temp February 29, 2024.

A replay of the decade. Seagen and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. Chris Boshoff, .wp config.temp Chief Oncology Officer and Executive Vice President, Pfizer. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our pipeline and scientific engine, and scale of the decade. Multiple near- and mid-term catalysts expected through the end of the decade.

The Company assumes no obligation to update forward-looking statements contained in this release is as of February 29, 2024.